Accessibility Menu
Sartorius Stedim Biotech logo

Sartorius Stedim Biotech(OTC) SDMHF

Market Cap$19.57BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)+403%
5 Year-64%
1 Year-2%
1 Month-7%
$208.48
+3.67%
+7.38Today
Sartorius Stedim Biotech last closing stock price
MetricPriceDate
Last closeUSD 201.102026-08-13
Sartorius Stedim Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.45%USD 202.002026-08-06
1 month-6.68%USD 215.502026-07-13
3 month+9.11%USD 184.312026-05-14
Year to date-17.91%USD 244.992025-12-31
1 year-1.82%USD 204.822025-08-13
3 year-30.01%USD 287.342023-08-14
5 year-63.7%USD 554.062021-08-13
Since inception+403.48%USD 39.942008-03-03

Sartorius Stedim Biotech Financials at a Glance

Market Cap

$19.57BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€3.01B

Net Income (TTM)

€292.90M

EPS (TTM)

$3.51

P/E Ratio

57.33

Dividend

$0.80

Beta (Volatility)

0.27 (Low)

Price

$208.48

Volume

11

Open

$208.48

Previous Close

$201.10

Daily Range

$208.48 - $208.48

52-Week Range

$178.30 - $264.30

Estimated Earnings Date

Oct 22, 2026

SDMHF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sartorius Stedim Biotech

Sartorius Stedim Biotech S.A. is a leading global provider of instruments and consumables for the biopharmaceutical industry. The company specializes in the production and sale of a wide range of products that support the development and manufacturing of medications, vaccines, and biological products.

Products and Services
  • Cell culture media and bioreactors for biopharmaceutical production
  • Advanced therapies and reagents for research and development
  • Fluid management services and microbiology testing instruments
Growth Outlook
  • Collaboration with Bio Usawa Biotechnology aims to enhance monoclonal antibody production
  • Increasing demand for biopharmaceuticals drives market expansion
  • Focus on innovative solutions positions the company for future growth
Financial Highlights
  • Q2 2026 revenue of €764.6 million, reflecting strong market demand
  • Net income of €92.9 million in Q2 2026, showcasing profitability
  • TTM gross profit margin of 44.87%, indicating operational efficiency
Sartorius Stedim Biotech S.A. operates in the healthcare sector, specifically within the medical specialties industry. The company has established a strong market presence, driven by its commitment to innovation and quality. Recent financial performance highlights a robust revenue stream and profitability, with a notable increase in net income in the latest quarter. The company's strategic collaborations and focus on advanced biopharmaceutical solutions position it well for continued growth in a rapidly evolving market. With a solid foundation and a clear growth trajectory, Sartorius Stedim Biotech S.A. presents an intriguing opportunity for potential investors.
AI Generated • Aug 7, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

10,477

CEO

René Fáber, PhD

Website

www.sartorius.com

Headquarters

Aubagne, PAC 13781, FR

SDMHF Financials

Key Financial Metrics (TTM)

Gross Margin

44.87%

Operating Margin

19.38%

Net Income Margin

9.74%

Return on Equity

7.11%

Return on Capital

8.21%

Return on Assets

3.70%

Earnings Yield

1.74%

Dividend Yield

0.40%

Payout Ratio

22.93%

Stock Overview

Market Cap

$19.57BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

97.30M

Volume

11

Avg. Volume

914.921

Financials (TTM)

Gross Profit

€1.35B

Operating Income

€559.02M

EBITDA

€1.45B

Operating Cash Flow

€615.62M

Capital Expenditure

-€394.61M

Free Cash Flow

€220.50M

Cash & ST Invst.

€203.59M

Total Debt

€2.40B

Sartorius Stedim Biotech Performance Analysis

Sartorius Stedim Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 3,670,737,9967.6%
20232023-12-31EUR 3,000,636,356-18.3%
20242024-12-31EUR 3,007,100,3030.2%
20252025-12-31EUR 3,349,055,06811.4%
Sartorius Stedim Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-5.1%
Q42025-12-319.2%
Q12026-03-31-1.0%
Q22026-06-300.0%
Sartorius Stedim Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 9.9988.0%
20232023-12-31EUR 3.64-63.6%
20242024-12-31EUR 1.96-46.2%
20252025-12-31EUR 3.0857.4%
Sartorius Stedim Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-4.3%
Q42025-12-31-25.8%
Q12026-03-3185.7%
Q22026-06-304.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€764.55M

+2.6%

Gross Profit

€358.26M

+3.9%

Gross Margin

46.86%

N/A

Market Cap

$19.57BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.91M

N/A

Employees

10,265

N/A

Net Income

€92.86M

+35.6%

EBITDA

€239.24M

+18.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€203.59M

-72.7%

Total Debt

€2.40B

-19.2%

Accounts Receivable

€327.71M

+24.2%

Inventory

€713.23M

+2.8%

Long Term Debt

€2.08B

-26.5%

Short Term Debt

€314.33M

+136.3%

Return on Assets

3.70%

N/A

Return on Invested Capital

8.63%

N/A

Free Cash Flow

€56.62M

+15.5%

Operating Cash Flow

€129.31M

+3.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SAUHYStraumann Holding AG
$12.65+0.45%
TRUMFTerumo Corporation
$13.69+0.00%
SAUHFStraumann Holding AG
$128.25+0.00%
SUVPFSartorius AG
$270.29+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.37+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.60-0.00%
INTCIntel
$103.04-0.01%
ONDSOndas
$9.47+0.06%

Questions About SDMHF

What is the current price of Sartorius Stedim Biotech?

Sartorius Stedim Biotech is trading at $208.48 per share.

What is the 52-week range for Sartorius Stedim Biotech?

Over the past 52 weeks, Sartorius Stedim Biotech has traded between $178.30 and $264.30.

How much debt does Sartorius Stedim Biotech have?

As of the most recent reporting period, Sartorius Stedim Biotech reported total debt of €2.75B.

How much cash does Sartorius Stedim Biotech have on hand?

Sartorius Stedim Biotech reported €233.12M in cash and cash equivalents in its most recent financial results.

What is Sartorius Stedim Biotech’s dividend yield?

Sartorius Stedim Biotech currently has a dividend yield of 0.40%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services